1. Cell Cycle/DNA Damage Epigenetics Neuronal Signaling
  2. HDAC Amyloid-β
  3. Santacruzamate A

Santacruzamate A  (Synonyms: CAY-10683)

製品番号: HY-N0931 純度: 99.54%
COA 取扱説明書 Technical Support

Santacruzamate A (CAY-10683, STA) is a potent and selective HDAC2 inhibitor with an IC50 of 119 pM. STA also exerts neuroprotective property against amyloid-β protein fragment 25–35. STA can be used for cancer and neurological disease research.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 1477949-42-0

容量 価格(税別) 在庫状況 数量
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
USD 60 在庫あり
Solution
10 mM * 1 mL in DMSO USD 60 在庫あり
Solid
5 mg $55 在庫あり
10 mg $65 在庫あり
25 mg $150 在庫あり
50 mg $250 在庫あり
100 mg $375 在庫あり
200 mg   お問い合わせ  
500 mg   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 19 publication(s) in Google Scholar

Other Forms of Santacruzamate A:

Top Publications Citing Use of Products

    Santacruzamate A purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2025 Oct 10:630:217901.  [Abstract]

    Western blot assay of lysates from HepG2 and MHCC97H cells treated with Santacruzamate A (CAY-10683) (20 μM; 48 h).

    Santacruzamate A purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2025 Oct 10:630:217901.  [Abstract]

    Santacruzamate A (CAY-10683) (20 μM; 24-72 h) impeded proliferation of HepG2 and MHCC97H cells.

    Santacruzamate A purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2025 Oct 10:630:217901.  [Abstract]

    Santacruzamate A (CAY-10683) (20 μM; 48 h) impeded the total cholesterol concentration of HepG2 and MHCC97H cells.

    Santacruzamate A purchased from MedChemExpress. Usage Cited in: Br J Pharmacol. 2024 Oct;181(19):3663-3684.  [Abstract]

    Santacruzamate A (CAY-10683) (0.1 μM; 24 h) significantly up-regulated the mRNA expression of FXR, SHP, and FGF19 in IEC-6 cells.

    Santacruzamate A purchased from MedChemExpress. Usage Cited in: Br J Pharmacol. 2024 Oct;181(19):3663-3684.  [Abstract]

    Santacruzamate A (CAY-10683) (2 mg/kg; i.p.; 1 h; once daily for 4 weeks) decreased the contents of total triglyceride (TG) and total cholesterol (TC) in the sera and livers and the activities of AST and ALT in the sera of NAFLD (non-alcohol fatty liver disease) mice.
    • 生物活性

    • 純度とドキュメンテーション

    • 参考文献

    • カスタマーレビュー

    製品説明

    Santacruzamate A (CAY-10683, STA) is a potent and selective HDAC2 inhibitor with an IC50 of 119 pM. STA also exerts neuroprotective property against amyloid-β protein fragment 25–35. STA can be used for cancer and neurological disease research[1][2].

    IC50 & Target[1]

    HDAC2

    119 pM (IC50)

    HDAC6

    434 nM (IC50)

    Cellular Effect
    Cell Line Type Value Description References
    HCT-116 GI50
    17.2 μM
    Compound: 1; SCA; isolated
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTS-PMS assay
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTS-PMS assay
    [PMID: 27614919]
    HCT-116 GI50
    28.3 μM
    Compound: 1, Synthetic SCA, santacruzamate A
    Cytotoxicity against human HCT116 cells after 96 hrs by MTS-PMS assay
    Cytotoxicity against human HCT116 cells after 96 hrs by MTS-PMS assay
    [PMID: 24164245]
    HCT-116 GI50
    29.4 μM
    Compound: 1, natural product, SCA, santacruzamate A
    Cytotoxicity against human HCT116 cells after 96 hrs by MTS-PMS assay
    Cytotoxicity against human HCT116 cells after 96 hrs by MTS-PMS assay
    [PMID: 24164245]
    HCT-116 GI50
    > 50 μM
    Compound: 1; SCA, synthetic
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTS-PMS assay
    Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability after 72 hrs by MTS-PMS assay
    [PMID: 27614919]
    HCT-116 IC50
    > 50 μM
    Compound: 5a; SCA
    Antiproliferative activity against human HCT116 cells after 24 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 24 hrs by MTT assay
    [PMID: 29100734]
    HCT-116 IC50
    > 50 μM
    Compound: 5a; SCA
    Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay
    [PMID: 29100734]
    HCT-116 IC50
    > 50 μM
    Compound: 5a; SCA
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay
    [PMID: 29100734]
    HuT78 GI50
    1.3 μM
    Compound: 1, Synthetic SCA, santacruzamate A
    Cytotoxicity against human HUT78 cells after 72 hrs by MTS-PMS assay
    Cytotoxicity against human HUT78 cells after 72 hrs by MTS-PMS assay
    [PMID: 24164245]
    HuT78 GI50
    1.4 μM
    Compound: 1, natural product, SCA, santacruzamate A
    Cytotoxicity against human HUT78 cells after 72 hrs by MTS-PMS assay
    Cytotoxicity against human HUT78 cells after 72 hrs by MTS-PMS assay
    [PMID: 24164245]
    HuT78 GI50
    36 μM
    Compound: 1; SCA; isolated
    Antiproliferative activity against human HUT78 cells assessed as reduction in cell viability after 70 hrs by Quanti-blue assay
    Antiproliferative activity against human HUT78 cells assessed as reduction in cell viability after 70 hrs by Quanti-blue assay
    [PMID: 27614919]
    HuT78 GI50
    > 50 μM
    Compound: 1; SCA, synthetic
    Antiproliferative activity against human HUT78 cells assessed as reduction in cell viability after 70 hrs by Quanti-blue assay
    Antiproliferative activity against human HUT78 cells assessed as reduction in cell viability after 70 hrs by Quanti-blue assay
    [PMID: 27614919]
    MCF7 GI50
    > 50 μM
    Compound: 1; SCA, synthetic
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTS-PMS assay
    Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by MTS-PMS assay
    [PMID: 27614919]
    MDA-MB-231 GI50
    > 50 μM
    Compound: 1; SCA, synthetic
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTS-PMS assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by MTS-PMS assay
    [PMID: 27614919]
    MOLT-4 GI50
    7.8 μM
    Compound: 1; SCA; isolated
    Antiproliferative activity against human MOLT4 cells assessed as reduction in cell viability after 70 hrs by Quanti-blue assay
    Antiproliferative activity against human MOLT4 cells assessed as reduction in cell viability after 70 hrs by Quanti-blue assay
    [PMID: 27614919]
    MOLT-4 GI50
    > 50 μM
    Compound: 1; SCA, synthetic
    Antiproliferative activity against human MOLT4 cells assessed as reduction in cell viability after 70 hrs by Quanti-blue assay
    Antiproliferative activity against human MOLT4 cells assessed as reduction in cell viability after 70 hrs by Quanti-blue assay
    [PMID: 27614919]
    PBMC GI50
    > 50 μM
    Compound: 1; SCA, synthetic
    Antiproliferative activity against human PBMC assessed as reduction in cell viability after 70 hrs by Quanti-blue assay
    Antiproliferative activity against human PBMC assessed as reduction in cell viability after 70 hrs by Quanti-blue assay
    [PMID: 27614919]
    体外実験

    Santacruzamate A (0.016-50 μM, 28 h) attenuates amyloid-β protein fragment 25–35-induced apoptosis and reverses Aβ25–35-induced unfolded protein response and endoplasmic reticulum stress in PC12 and SH-SY5Y. 2 μM STA shows the strongest protective effects[2].
    Santacruzamate A (0.016-50 μM, 12 h) up-regulates KDEL receptor (KDELR) expression, reinforces ER luminal retention of chaperones, and enhances the binding of PERK to GRP78, inhibiting the amyloid-β protein fragment 25–35-induced mitochondrial fission and apoptosis pathways in PC12[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    分子量

    278.35

    分子式

    C15H22N2O3

    CAS 番号
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    O=C(OCC)NCCCC(NCCC1=CC=CC=C1)=O

    Structure Classification
    Initial Source

    Panamanian Marine Cyanobacterium

    輸送条件

    Room temperature in continental US; may vary elsewhere.

    保管条件
    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    溶剤 & 溶解度
    体外: 

    DMSO : ≥ 100 mg/mL (359.26 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 3.5926 mL 17.9630 mL 35.9260 mL
    5 mM 0.7185 mL 3.5926 mL 7.1852 mL
    10 mM 0.3593 mL 1.7963 mL 3.5926 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます:C1V1 = C2V2

    濃度 (開始)

    C1

    ×
    体積 (開始)

    V1

    =
    濃度 (終了)

    C2

    ×
    体積 (終了)

    V2

    体内:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (8.98 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.5 mg/mL (8.98 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    純度とドキュメンテーション

    純度: 99.54%

    参考文献

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 3.5926 mL 17.9630 mL 35.9260 mL 89.8150 mL
    5 mM 0.7185 mL 3.5926 mL 7.1852 mL 17.9630 mL
    10 mM 0.3593 mL 1.7963 mL 3.5926 mL 8.9815 mL
    15 mM 0.2395 mL 1.1975 mL 2.3951 mL 5.9877 mL
    20 mM 0.1796 mL 0.8981 mL 1.7963 mL 4.4907 mL
    25 mM 0.1437 mL 0.7185 mL 1.4370 mL 3.5926 mL
    30 mM 0.1198 mL 0.5988 mL 1.1975 mL 2.9938 mL
    40 mM 0.0898 mL 0.4491 mL 0.8981 mL 2.2454 mL
    50 mM 0.0719 mL 0.3593 mL 0.7185 mL 1.7963 mL
    60 mM 0.0599 mL 0.2994 mL 0.5988 mL 1.4969 mL
    80 mM 0.0449 mL 0.2245 mL 0.4491 mL 1.1227 mL
    100 mM 0.0359 mL 0.1796 mL 0.3593 mL 0.8981 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質量   濃度   体積   分子量 *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます:C1V1 = C2V2

    濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    最近チェックした製品:

    オンラインお問い合わせ

    Your information is safe with us. * Required Fields.

    製品名

     

    カスタマ需要量 *

    お名前 *

     

    タイトル

    メールアドレス *

     

    電話番号 *

    デパートメント

     

    組纖名 *

    市区町村

    都道府県

    国或いは地域 *

         

    必ず会社名を記載ください。個人への返信は行いません。

    備考

    バルクお問い合わせ

    Inquiry Information

    製品名:
    Santacruzamate A
    製品番号:
    HY-N0931
    数量:
    MCE 日本正規代理店: